Related content

A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma

By Amato Robert   Khan Muhammad  

Cancer Chemotherapy and Pharmacology, Vol. 61, Iss. 6, 2008-05 ,pp. : 1069-1073

Springer Publishing Company

Access to resources Recommend Favorite

Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis

By  

Molecular and Clinical Oncology, Vol. 3, Iss. 2, 2015-01 ,pp. : 322-328

Science Publishers

Access to resources Recommend Favorite

Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma

By                

International Journal of Oncology, Vol. 41, Iss. 2, 2012-01 ,pp. : 712-720

Spandidos Publications

Access to resources Recommend Favorite

Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo

By                    

Molecular Medicine Reports, Vol. 12, Iss. 5, 2015-01 ,pp. : 6727-6737

Spandidos Publications

Access to resources Recommend Favorite

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer - a phase II study.

By Allen M.   Vaughan M.   Webb A.   Johnston S.   Savage P.   Eisen T.   Bates S.   Morre J.   Ahern R.   Gore M.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 2, 2002-03 ,pp. : 83-83

Elsevier

Access to resources Recommend Favorite